** Shares of biotechnology firm Windtree Therapeutics WINT.O rise 27.8% to $2.16 in afternoon trading
** WINT says it has entered into a licensing deal with Evofem Biosciences EVFM.PK for its birth control vaginal gel, Phexxi
** WINT will serve as the sourcing partner to Evofem and aims to produce Phexxi at a cheaper cost
** Co says Evofem will maintain ownership of the asset and continue to commercialize Phexxi in the U.S. and internationally
** Up to last close, WINT has fallen 99.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.